반복되는 메치실린 내성 황색포도알균 균혈증에 의하여 발생한 화 농성 관절염을 Linezolid로 치료한 1예
A Case of Septic Arthritis Caused by Persistent MRSA Bacteremia with Successful Treatment Through Linezolid
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Vancomycin is the primary antibiotic administered for treatment of methicillinresistant S. aureus (MRSA) infection; however, treatment failure of vancomycin is currently not uncommon in patients with in vitro vancomycin susceptibile S. aureus (MIC ≤ 2 μg/mL) infection. In this report, we describe a case of septic arthritis caused by persistent MRSA bacteremia and treated successfully with linezolid after failure of initial vancomycin therapy.
Abstract
Vancomycin is the primary antibiotic administered for treatment of methicillinresistant S. aureus (MRSA) infection; however, treatment failure of vancomycin is currently not uncommon in patients with in vitro vancomycin susceptibile S. aureus (MIC ≤ 2 μg/mL) infection. In this report, we describe a case of septic arthritis caused by persistent MRSA bacteremia and treated successfully with linezolid after failure of initial vancomycin therapy.
참고문헌 (18)
- Khatib R., "Persistent Staphylococcus aureus bacteremia : incidence and outcome trends over time", Scand J Infect Dis, 41, pp.4~9 (2009)
- Fowler VG Jr., "Clinical identifiers of complicated Staphylococcus aureus bacteremia", Arch Intern Med, 163, pp.2066~2072 (2003)
- Yoshida T., "Potent in vitro bactericidal activity of polymyxin B against methicillin-resistant Staphylococcus aureus(MRSA)", Microbiol Immunol, 37, pp.853~859 (1993)
- Moellering RC Jr., "New treatments for multiply drug-resistant Gram-positive bacteria", J Infect, 59(Suppl 1), pp.S1~S3 (2009)
- Wilcox MH., "Complicated skin and skin-structure infections and catheter-related bloodstream infections : noninferiority of linezolid in a phase 3 study", Clin Infect Dis, 48, pp.203~212 (2009)
- Yoon YK., "Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin", J Antimicrob Chemother, 65, pp.1015~1018 (2010)
- Tenover FC., "The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus", Clin Infect Dis, 44, pp.1208~1215 (2007)
- Howden BP., "Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains : resistance mechanisms, laboratory detection, and clinical implications", Clin Microbiol Rev, 23, pp.99~139 (2010)
- Sakoulas G., "Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia", J Clin Microbiol, 42, pp.2398~2402 (2004)
- Falagas ME., "Linezolid for the treatment of adults with bone and joint infections", Int J Antimicrob Agents, 29, pp.233~239 (2007)
- De Bels D., "Successful treatment with linezolid of septic shock secondary to methicillin-resistant Staphylococcus aureus arthritis", J Antimicrob Chemother, 55, pp.812~813 (2005)
- Sakoulas G., "Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains", Clin Infect Dis, 46(Suppl 5), pp.S360~S367 (2008)
- Jang HC., "Salvage Treatment for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Efficacy of Linezolid With or Without Carbapenem", CLINICAL INFECTIOUS DISEASES, 49(12), pp.395~401 (2009), UNIV CHICAGO PRESS
- Falagas ME., "Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections : meta-analysis of randomised controlled trials", Lancet Infect Dis, 8, pp.53~66 (2008)
- Beibei L., "Linezolid versus vancomycin for the treatment of gram-positive bacterial infections : meta-analysis of randomised controlled trials", Int J Antimicrob Agents, 35, pp.3~12 (2010)
- Lu PL., "Compassionate use of linezolid for adult Taiwanese patients with bone and joint infections", Chemotherapy, 56, pp.429~435 (2010)
- Kutscha-Lissberg F., "Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci", Antimicrob Agents Chemother, 47, pp.3964~3966 (2003)
- Orrick JJ., "Thrombocytopenia secondary to linezolid administration : what is the risk?", Clin Infect Dis, 35, pp.348~349 (2002)